The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?
Abstract
Abstract Learning Objectives After completing this course, the reader will be able to:Describe the current limitations in measuring levels of EGR receptor (EGFR) expression in tissues.Identify the molecular pathways for signal transduction induced by EGFR activation.Identify the level of expression of EGF in different tumor types. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com The epidermal growth factor receptor (EGFR) is a rational target for antitumor strategies. EGFR signaling causes increased proliferation, decreased apoptosis, and enhanced tumor cell motility and neo-angiogenesis. The EGFR is expressed or highly expressed in a variety of human tumors of epithelial origin. ZD1839 (Iressa™) is an orally active, selective EGFR tyrosine kinase inhibitor, which blocks signal transduction pathways implicated in proliferation and survival of cancer cells. The lack of a consistent method of evaluating levels of EGFR has caused a disparity in reports of the EGFR as a prognostic factor; however, for some tumors, EGFR is a strong prognostic indicator associated with more aggressive disease and reduced survival. So far, no clear association between EGFR levels and response to EGFR-targeted agents has been found. Preclinical studies with ZD1839 have noted a relationship between the two in some cases, but not others. EGFR signaling may be increased by a number of mechanisms in addition to high expression levels of EGFR, including receptor mutations, heterodimerization with other members of this receptor family such as HER2 (erbB2), increased expression of (autocrine/ paracrine) ligands, and alterations in molecules that control receptor signaling output. Each of these components could be assessed to give an indication of the magnitude of EGFR signal amplification. Evaluation of signaling components downstream from EGFR should provide information on the activation of the EGFR pathway. Until EGFR-based assays predictive of a response to receptor-targeted therapies are available, there is no clear justification for stratifying patients by EGFR status or excluding patients with low EGFR levels from trials with ZD1839 or other EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 5×
“These effects are mediated by a complex series of signaling mechanisms, such as engagement of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) pathways (Fig. 1) [ 2 ].”
BackgroundMethodInfluentialEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.
Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G. R., Zoltick, P. W., Biegel, J. A., Hayes, R. L., & Wong, A. J. (1995) · PubMed · Cited by 637
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 597
Self-citationMoasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 555
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R. S., LoRusso, P. M., Rischin, D., Sauleda, S., Gee, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.110 · Cited by 528
Rude Voldborg, B., Damstrup, L., Spang-Thomsen, M., & Skovgaard Poulsen, H. (1997) · Annals of Oncology · doi:10.1023/a:1008209720526 · Cited by 528
Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D. K., Pegram, C. N., & Reist, C. J. (1995) · PubMed · Cited by 518
Gschwind, A., Zwick, E., Prenzel, N., Leserer, M., & Ullrich, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204192 · Cited by 462
Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D. S., Hölscher, A. H., & Danenberg, P. V. (2001) · PubMed · Cited by 452
Rusch, V. W., Klimstra, D. S., Venkatraman, E. S., Pisters, P. W. T., Langenfeld, J. E., & Dmitrovsky, E. (1997) · PubMed · Cited by 401
Filardo, E. J. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00190-x · Cited by 373
Xia, W., Lau, Y. K. J., Zhang, H. Z., Xiao, F. Y., Johnston, D. A., Liu, A. R., Li, L., Katz, R. L., & Hung, M. (1999) · PubMed · Cited by 327
Worthylake, R., Opresko, L. K., & Wiley, H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8865 · Cited by 325
Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways
Carpenter, G. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.4.697 · Cited by 272
Ohsaki, Y., Tanno, S., Fujita, Y., Toyoshima, E., Fujiuchi, S., Nishigaki, Y., Ishida, S., Nagase, A., Miyokawa, N., Hirata, S., et al. (2000) · Oncology Reports · doi:10.3892/or.7.3.603 · Cited by 254
Birner, P., Oberhuber, G., Stani, J., Reithofer, C., Samonigg, H., Hausmaninger, H., Kubista, E., Kwasny, W., Kandioler-Eckersberger, D., Gnant, M., et al. (2001) · PubMed · Cited by 197
Anderson, N. G., Ahmad, T., Chan, K., Dobson, R., & Bundred, N. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1557 · Cited by 197
Newby, J. C., Johnston, S. R. D., Smith, I. E., et al. (1997) · PubMed · Cited by 192
Perez-Soler, R. (2001) · Medical Entomology and Zoology · Cited by 189
Nicholson, R. I., McClelland, R. A., Finlay, P., Eaton, C. L., Gullick, W. J., Dixon, A. R., Robertson, J. F. R., Blamey, R. W., & Ellis, I. O. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80215-1 · Cited by 178
Volm, M., Rittgen, W., & Drings, P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.106 · Cited by 178
Prenzel, N., Zwick, E., Leserer, M., & Ullrich, A. (2000) · Breast Cancer Research · doi:10.1186/bcr52 · Cited by 166
Nicholson, R. I., Hutcheson, I. R., Harper, M. E., Knowlden, J. M., Barrow, D., McClelland, R. A., Jones, H. E., Wakeling, A. E., & Gee, J. M. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080175 · Cited by 159
Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3
Chen, X., Yeung, T. K., & Wang, Z. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3731 · Cited by 158
Fischer-Colbrie, J., Witt, A., Heinzl, H., Speiser, P., Czerwenka, K. F., Sevelda, P., & Zeillinger, R. (1997) · PubMed · Cited by 156
Tyrosine kinase signalling in breast cancer
Hynes, N. E. (2000) · Breast Cancer Research · doi:10.1186/bcr48 · Cited by 138
Knoop, A. S., Bentzen, S. M., Nielsen, M. M., Rasmussen, B., & Rose, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3376 · Cited by 122
Patterns of epidermal growth factor receptor amplification in malignant gliomas.
Sauter, G., MAEDA, T., Waldman, F. M., Davis, R. L., & Feuerstein, B. G. (1996) · Europe PMC (PubMed Central) · Cited by 112
Harari, P. M., & Huang, S. (2001) · Seminars in Radiation Oncology · doi:10.1053/srao.2001.26027 · Cited by 100
Kurokawa, H., & Arteaga, C. L. (2001) · PubMed · Cited by 94
Self-citationCohen, D., Simak, R., Fair, W. R., et al. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)32335-2 · Cited by 93
Tateishi, M., Ishida, T., Kohdono, S., Hamatake, M., Fukuyama, Y., & Sugimachi, K. (1994) · Surgical Oncology · doi:10.1016/0960-7404(94)90006-x · Cited by 87
Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas.
Gorgoulis, V. G., Aninos, D., Mikou, P., Kanavaros, P., Karameris, A., Joardanoglou, J., Rasidakis, A., Veslemes, M., Ozanne, B. W., & Spandidos, D. A. (1992) · PubMed · Cited by 84
Hsieh, E., Shepherd, F. A., & Tsao, M. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00116-1 · Cited by 66
Magné, N., Pivot, X. B., Bensadoun, R., Guardiola, E., Poissonnet, G., Dassonville, O., Francoual, M., Formento, J., Demard, F., Schneider, M., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00280-5 · Cited by 59
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Wakeling, A. E., Nicholson, R. I., & Gee, J. M. W. (2001) · PubMed · Cited by 50
Nešković‐Konstantinović, Z., Nikolić‐Vukosavljević, D., Brankovic-Magic, M. V., et al. (1999) · PubMed · Cited by 17
Cited by
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Ohgaki, H., & Kleihues, P. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.479 · Cited by 1,381
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Metadata
- Authors
- Arteaga, C. L.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-08-15
- Volume
- 7
- Issue
- 90004
- Pages
- 31-39
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2163252214
- Cited by
- 455
- References
- 46
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.